MeMed BV
Delivers a Breakthrough
in Rapid Diagnostics
Our 15-minute test differentiates between bacterial and
viral infections, empowering patients, optimizing
provider workflows, and strengthening public health.
MeMed BV® delivers a breakthrough
in rapid diagnostics
Our 15-minute test differentiates between bacterial and viral infections, empowering patients, optimizing provider workflows, and strengthening public health.
Minimizing
Clinical
Uncertainty1
Reducing
Potentially Unwarranted
antibiotic prescriptions2
Outperforming
lab tests and clinical
parameters3
Aiding
operational
challenges
Reducing
Potentially Unwarranted
antibiotic prescriptions1
Minimizing
Clinical
Uncertainty2
Outperforming
lab tests and clinical
parameters3
Aids in
operational
challenges
The Immune System is Built to Communicate
Our Mission is to Listen.
We apply machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed’s machine learning-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders.
MeMed BV
Bacterial and viral infections are often clinically indistinguishable and can lead to inappropriate patient management and antibiotic misuse.4
MeMed BV® is the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes.
MeMed Key
MeMed Key® is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, quick, multiplexed protein measurements that previously could only be done on large, expensive central lab equipment.
Together, MeMed Key and MeMed BV help physicians make better decisions in the management of patients with acute infections.
Clinical
Evidence
Clinical Evidence
Testimonials
“We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infecation, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made big difference in the patient’s outcome. Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.”
Adi Klein, MD
Director of Pediatric Division, Hillel Yaffe Medical Center
and Head of the Israeli Clinical Pediatric Society
“Every day, I see patients with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technology like MeMed BV can significantly aid in their management.”
Sergey Motov, MD
Professor of Emergency Medicine, Maimonides Medical
Center, New York
“It’s a game-changer, when children come in with a cough, we can for the first time discover accurately whether they have a bacterial infection, in which case we give them an antibiotic, or a viral infection, when we don’t.”
Louis Bont, MD
Professor of Pediatric Immunity and Infectious Disease, Utrecht’s University Medical
Netherland
Mylinda Dill, PharmD
Director of Pharmacy, Division of Aging, Adult, and Behavioral Health Services, Arkansas State Hospital
“We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infecation, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made big difference in the patient’s outcome. Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.”
Adi Klein, MD
Director of Pediatric Division, Hillel Yaffe Medical Center and Head of the Israeli Clinical Pediatric Society:
“Every day, I see patients with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technoloy like MeMed BV can significantly aid in their management.”
Sergey Motov, MD
Professor of Emergency Medicine, Maimonides Medical Center, New York
“”IT’s a game-changer, when children come in with a cough, we can for the first time discover accurately whether they have a bacterial infection, in which case we give them an antibiotic, or a viral infection, when we don’t.”
Louis Bont, MD
Professor of Pediatric Immunity and Infectious Disease, Utrecht’s University Medical, Netherlands
“It’s a great tool for antimicrobial stewardship. We reduced our outpatient antibiotic prescribing rate by 20% after we implemented MeMed BV. You have to remember, simply using antibiotics creates resistance, so every unnecessary antibiotic we DON’T prescribe is important in the never-ending war against antimicrobial resistance. Plus it isn’t expensive…”
Mylinda Dill, PharmD
Director of Pharmacy, Division of Aging, Adult, and Behavioral Health Services, Arkansas State Hospital
Our Partners
Awards & Prizes
References
- Kalmovich, B., Rahamim-Cohen, D., Yehoshua, I. et al. Implementation of a rapid host-protein diagnostic test for distinguishing bacterial and viral infections in adults presenting to urgent care centers: a pragmatic cohort study. BMC Med 23, 63 (2025).
- Kalmovich B, Rahamim-Cohen D, Shapiro Ben David S. Impact on patient management of a novel host response test for distinguishing bacterial and viral infections: Real world evidence from the urgent care setting. Biomedicines. 2023 May 22;11(5):1498.
- Coburn Allen, et al. Development of a Reference Standard to Assign Bacterial Versus Viral Infection Etiology Using an All-inclusive Methodology for Comparison of Novel Diagnostic Tool Performance. Clinical Infectious Diseases, 2025;
- Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS One. 2015 Mar 18;10(3):e0120012.
- MeMed data on file. Based on secondary endpoint analysis in Apollo Clinical Study (NCT04690569).
- van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
- Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
- Papan C, Argentiero A, Porwoll M, Hakim U, Farinelli E, Testa I, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: A prospective, multicentre cohort study. Clin Microbiol Infect. 2022 May 1;28(5):723-30.
- Halabi S, Shiber S, Paz M, Gottlieb TM, Barash E, Navon R, et al. Host test based on TRAIL, IP-10 and CRP for differentiating bacterial and viral respiratory tract infections in adults: Diagnostic accuracy study. Clin Microbiol Infect. 2023 Jun 1.
- Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.
- Mor M, Paz M, Amir L, Levy I, Scheuerman O, Livni G, et al. Bacterial vs viral etiology of fever: A prospective study of a host score for supporting etiologic accuracy of emergency department physicians. PLoS One. 2023 Jan 30;18(1):e0281018.
- Chokkalla AK, Tam E, Liang R, Cruz AT, Devaraj S. Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort. Clin Chim Acta. 2023 Jun 1;546:117387.
